Company intelligence / Profile preview

CrystecPharma

Ownership: Private
Development stage: Commercial

Overview

mSAS® platform enables rapid development of stable, free-flowing powders for both small and large molecules. 100% success rate reported for biomolecule projects completed since 2022. No major clinical trial results published; focus is on enabling technology rather than proprietary drugs.

Therapeutic areas: PulmonologyMen's HealthWomen's Health
Modalities: Small moleculeBiologicProtein
Industry: Drug Discovery Services

Beyond the preview

Go deeper on CrystecPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CrystecPharma.

Explore the full profile